Drug Trial Radar · NCT07163143
Optimal Treatment Duration for Radiographically Apparent, Bacteriologically Unconfirmed TB, Identified Through Active Case Finding (RADIO-TB Trial)
Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
784
Planned (sponsor's estimate)
Start
Oct 12, 2026
Primary completion
Nov 2028
Study completion Apr 2029
Sponsor
- Lead sponsor
- University College, LondonAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National University of Medical Sciences, Pakistan; Aurum Institute; Biomedical Research and Training Institute, Zimbabwe; Foundation for Innovative New Diagnostics, Switzerland; KTH Royal Institute of Technology; London School of Hygiene and Tropical Medicine; Wits Health Consortium (Pty) Ltd
- First posted
- Sep 9, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
People living in high TB burden communities who undergo active case finding for TB may have chest X-ray changes suggestive of TB but their sputum test can be negative for the TB bacteria or they are unable to provide a sputum sample. This means they have bacteriologically unconfirmed TB. These individuals often have minimal or no symptoms and face uncertainty in clinical management-either receiving full 24-weeks TB treatment or often being discharged without treatment, risking loss to follow-up. The RADIO-TB trial aims to address the following main questions in relation to people with bacteriologically unconfirmed TB. 1. What is the risk of progression if treatment is not immediately started but there is close and careful follow-up over 78 weeks? 2. If treatment is started immediately what is the shortest duration of TB treatment that is as effective as the standard 24-week TB treatment? 3. Are there better tests to confirm TB than the current routinely used, sputum-based tests? 4. What is the cost effectiveness of different treatment strategies and what might the impact on transmission be within communities? Participants in the trial will be randomized into six groups: five receiving immediate standard TB treatment of varying durations (8 to 24 weeks), and one receiving deferred treatment with close monitoring. Deferred treatment will be initiated only if clinical deterioration occurs or TB is later confirmed. Participants will be closely followed for 78 weeks with at least 11 clinic visits.
Conditions
- Tuberculosis (TB)
Interventions
Isoniazid (H)Drug
H, weight based, 150-375mg
Rifampicin (R)Drug
R, weight based, 300-750mg
Pyrazinamide (Z)Drug
Z, weight based, 800-2000mg
Ethambutol (E)Drug
E weight based, 550-1375mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants with an unfavourable TB outcomeTime frame: Over 78 weeks post-randomisation
Locations
4 sites in 3 countries. Site status is shown where the registry gives one.
National University of Medical Sciences
Islamabad, Pakistan · Not yet recruiting
Clinical HIV Research Unit, Wits Health Consortium
Johannesburg, South Africa · Not yet recruiting
The Aurum Institute
Johannesburg, South Africa · Not yet recruiting
Bulawayo City Health
Bulawayo, Zimbabwe · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.